Chromosomal Microarrays Market

According to the latest research by Persistence Market Research, Chromosomal Microarrays market is set to witness a growth of 8.7% during the forecast period. Demand for Chromosomal Microarrays is expected to show stable growth during the forecast period. The development and demand for the Chromosomal Microarrays market industry will offer beneficial opportunities for the providers in near future.

There is an increase in the funding in the research for genetic testing and rising use of microarrays in gene discovery along with application in disease diagnostics and toxicology research. All these factors are supposed to facilitate the growth of chromosomal microarrays demand outlook in the forecast period.

Other factors that would be contributing to the increasing demand for chromosomal microarrays are the rise in cancer cases, to-be-parents wanting to know about their baby’s developmental disorders before birth and a wide range of applications such as gene sequencing, genome mapping, and personalized medication.

There is a steep rise in the global Research and Development investments in the chromosomal microarrays sector, which is proving to be a leading factor in propelling the demand outlook for the field. There are also various array platforms introduced in the market by leading manufacturers which is another factor anticipated to increase the potential of this market.

In a research study published by Radboud University Medical Center, on July 7th, 2021, it is stated that Optical Genome Mapping (OGM) is the latest technology used in detecting abnormalities in chromosomes at a faster rate, accurately and efficiently both. They stated it can sometimes be even better than all the other techniques available for genome mapping and next generation sequencing.

The Optical Genome Mapping Technique is set to revolutionize the sector and existing workflow within the laboratories. This Next Generation Cytogenetics technique is anticipated to replace the routine genetic testing and thereby vastly improve workflow and ultimately patient care.

The U.S. and Canada Regional demand for chromosomal microarrays held the largest market share in the past and are anticipated to keep on growing in the forecast period as well. Rise in the number of cancer patients is one of the major driver for this field in the region.

In 2018, Merck signed an agreement with Histocyte Laboratories Ltd, to facilitate the distribution of cell microarrays in the U.S., which was aimed to help researchers by providing them with an easy, cost effective option.

The European Chromosomal Microarrays market hold second largest share globally. The government of Europe, in April 2021, funded a staggering $ 7. 5 billion dollars in the field of R&D for biotechnology.

This injection of funds is expected to contribute to the rising use of microarrays for various genome testing in the region. This Factor will contribute to the major advancement of the Chromosomal Microarrays market in Europe in the forthcoming years.

The key players in this industry include

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories
• MedGenome
• Scott Minifab
• Agilent technologies Inc.
• Perkin Elmer Inc.
• Illumina Inc.
• Microarrays Inc.
• Merck KGaA
• Arrayit Corporation
• GE Healthcare
• Molecular Devices LLC.

Thermo Fisher Scientific, in 2017, launched a product called “Axiom Africa array”. This product was launched for the African population along with Europe and Asia for capturing genome wide variations found in the population.

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance
• Must-have information for market players to sustain and enhance their market footprint

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.